Physician profile
Thuy Tran
NPI 1851736938
$737.53
in general payments reported to CMS, 2019-2025
10 companies · $58.10 in 2025
The $58.10 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $163 · 2023: $116 · 2024: $279 · 2025: $58.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $134.46 | 2024 | Gvoke Hypopen |
| Stryker Corporation | $128.74 | 2021 | |
| Lilly USA, LLC | $116.33 | 2023 | Taltz |
| Intuitive Surgical, INC. | $104.05 | 2024 | |
| Merck Sharp & Dohme LLC | $98.09 | 2020 | |
| Iovance Biotherapeutics, INC. | $58.10 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $40.70 | 2024 | Fruzaqla |
| Abbott Laboratories | $23.11 | 2020 | |
| Janssen Biotech, INC. | $17.95 | 2021 | |
| Genentech USA, INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.